Additionally, the 36-month beta value for IGC is 1.45. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IGC is 55.48M and currently, short sellers hold a 1.76% ratio of that float. The average trading volume of IGC on March 26, 2025 was 397.76K shares.
IGC) stock’s latest price update
The stock price of IGC Pharma Inc (AMEX: IGC) has jumped by 3.76 compared to previous close of 0.31. Despite this, the company has seen a gain of 1.83% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-26 that – IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer’s – POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC Pharma” or the “Company”) today announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer’s disease. Based on the interim analysis at week 2 sleep disturbance was reduced by about 71% (p=.012) and at week 6 about 78% (p=.02) for those on the active medication.
IGC’s Market Performance
IGC’s stock has risen by 1.83% in the past week, with a monthly rise of 11.06% and a quarterly drop of -16.28%. The volatility ratio for the week is 5.38% while the volatility levels for the last 30 days are 7.87% for IGC Pharma Inc The simple moving average for the past 20 days is 2.85% for IGC’s stock, with a -14.50% simple moving average for the past 200 days.
IGC Trading at 1.39% from the 50-Day Moving Average
After a stumble in the market that brought IGC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.13% of loss for the given period.
Volatility was left at 7.87%, however, over the last 30 days, the volatility rate increased by 5.38%, as shares surge +11.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.42% lower at present.
During the last 5 trading sessions, IGC rose by +1.83%, which changed the moving average for the period of 200-days by -26.69% in comparison to the 20-day moving average, which settled at $0.3085. In addition, IGC Pharma Inc saw -5.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IGC starting from Moran James P, who purchase 588,235 shares at the price of $0.34 back on Sep 25 ’24. After this action, Moran James P now owns 942,402 shares of IGC Pharma Inc, valued at $200,000 using the latest closing price.
PRINS RICHARD K, the Director of IGC Pharma Inc, proposed sale 200,000 shares at $0.39 during a trade that took place back on Aug 12 ’24, which means that PRINS RICHARD K is holding shares at $78,200 based on the most recent closing price.
Stock Fundamentals for IGC
Current profitability levels for the company are sitting at:
- -6.64 for the present operating margin
- 0.51 for the gross margin
The net margin for IGC Pharma Inc stands at -7.13. The total capital return value is set at -1.28. Equity return is now at value -115.06, with -86.63 for asset returns.
Based on IGC Pharma Inc (IGC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.45.
Currently, EBITDA for the company is -9.16 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 19.72. The receivables turnover for the company is 13.43for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.15.
Conclusion
In conclusion, IGC Pharma Inc (IGC) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
